Research programme: coronavirus vaccines - BioNtech/Pfizer
Alternative Names: 2019-nCoV mRNA vaccines - BionTech/Pfizer; BNT-162 vaccine programme; COVID-2019 vaccines - BionTech/Pfizer; mRNA vaccines - BionTech/Pfizer; Project Lightspeed; SARS-CoV-2 virus vaccines - BionTech/PfizerLatest Information Update: 28 May 2024
At a glance
- Originator BioNTech
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Germany (Parenteral)
- 05 May 2023 Arbutus Biopharma files patent infringement lawsuit against Pfizer and BioNTech seeking compensation for use of unlicensed patented technologies in COVID-19 mRNA-LNP vaccines